BRIEF published on 04/16/2024 at 13:05, 1 year 7 months ago CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
PRESS RELEASE published on 04/16/2024 at 13:00, 1 year 7 months ago CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF published on 04/04/2024 at 13:05, 1 year 8 months ago CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
BRIEF published on 04/04/2024 at 13:05, 1 year 8 months ago CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
PRESS RELEASE published on 04/04/2024 at 13:00, 1 year 8 months ago CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE published on 11/01/2023 at 13:00, 2 years 1 month ago CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE published on 09/28/2023 at 13:00, 2 years 2 months ago CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE published on 09/12/2023 at 13:15, 2 years 2 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 09/12/2023 at 13:00, 2 years 2 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 08/17/2023 at 13:00, 2 years 3 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Published on 12/05/2025 at 15:35, 7 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:00, 42 minutes ago Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 42 minutes ago Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 42 minutes ago Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 15:38, 4 minutes ago Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 7 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/05/2025 at 15:33, 8 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/05/2025 at 15:32, 9 minutes ago Form 8.3 - The Vanguard Group, Inc.: Alphawave IP Group plc
Published on 12/05/2025 at 15:10, 31 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 31 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 43 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 57 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 57 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
